Other

Pfizer Corporation

Warner-lambert Company

Athersys, Inc.

James Thomas Anderson

Patrick Robert Verhoest

Adam Matthew Gilbert

Peter Laurence Toogood

Rayomand Jal Unwalla

J Nigel Ellis

Eugene Lvovich Piatnitski Chekler

Edward Neil Marsh

Eugene Lvovich Chekler

Youssef L Bennani

Edmund Lee Ellsworth

Jianmin Wang

Michael G Campbell

Anthony P Ricketts

Bruce Kipp Erickson

David P Thompson

The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or &#x2014;CR&#x2014;, where Ris hydrogen, C-Clinear or branched chain alkyl, etc., Z is &#x2014;CR&#x2014;, or, &#x2014;N&#x2014;, where Ris hydrogen, C-Clinear or branched chain alkyl, etc.; Ris hydrogen, C-Clinear or branched chain alkyl, etc.; Rare independently hydrogen or C-Clinear or branched chain alkyl; Rand Rare independently hydrogen, C-Clinear or branched chain alkyl, etc.; Rand Rare independently hydrogen or C-Clinear or branched chain alkyl, etc.; Ris hydrogen, C-Clinear or branched chain alkyl, etc.; Rand Rare independently hydrogen or C-Clinear or branched chain alkyl, etc.; Q is &#x2014;CO&#x2014;, &#x2014;(CH)&#x2014;, &#x2014;(CHR)&#x2014;, or &#x2014;(CRR)&#x2014;, where Rand Rare independently C-Clinear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, for the treatment of certain diseases, particularly those affected or mediated by the androgen receptor; to combinations comprising such compounds with a second pharmaceutically active ingredient; to compositions containing such combinations; and to such combinations for the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.

Methods of use and combinations

The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or &#x2014;CR&#x2014;, where Ris hydrogen, C-Clinear or branched chain alkyl, etc., Z is &#x2014;CR&#x2014;, or, &#x2014;N&#x2014;, where Ris hydrogen, C-Clinear or branched chain alkyl, etc.; Ris hydrogen, C-Clinear or branched chain alkyl, etc.; Rare independently hydrogen or C-Clinear or branched chain alkyl; Rand Rare independently hydrogen, C-Clinear or branched chain alkyl, etc.; Rand Rare independently hydrogen or C-Clinear or branched chain alkyl, etc.; Ris hydrogen, C-Clinear or branched chain alkyl, etc.; Rand Rare independently hydrogen or C-Clinear or branched chain alkyl, etc.; Q is &#x2014;CO&#x2014;, &#x2014;(CH)&#x2014;, &#x2014;(CHR)&#x2014;, or &#x2014;(CRR)&#x2014;, where Rand Rare independently C-Clinear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.

Selective androgen receptor modulators

A portable safety ladder assembly having safety extensions to permit safe and easy access to landing areas, working platforms, scaffolds, etc. The safety extension members have a plurality of horizontal handgrips ergonomically designed to prevent falls from the ladder assembly when a user is ascending upward or descending downward thereon.

Portable safety ladder assembly

A safety ladder assembly and a safety extension used in combination with a ladder suitable to permit safe and easy access to the landing areas, working platforms, scaffolds, etc. The assembly includes safety extension members having a plurality of horizontal handgrips ergonomically designed to prevent falls from the ladder when a user is ascending upward or descending downward.

This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain non-imidazole tertiary amine derivatives and their salts and solvates. These compounds have Hhistamine receptor antagonist activity. This invention also relates to pharmaceutical compositions containing these compounds and to a method of treating disorders in which histamine Hreceptor blockade is beneficial.

Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders

A process for synthesizing L and D-5,5,5,5',5&#x2032;,5&#x2032;-hexafluoroleucine and protected analogs is disclosed. These compounds have utility in the preparation of fluorous peptides and proteins, which display interesting and unusual properties including strong self-association and an affinity for lipid bilayers.

Process for preparing single enantiomers of 5,5,5,5',5&#x2032;,5&#x2032;-hexafluoroleucine and protected analogs

A process for synthesizing L and D-5,5,5,5&prime;,5&prime;,5&prime;-hexafluoroleucine and protected analogs is disclosed. These compounds have utility in the preparation of fluorous peptides and proteins, which display interesting and unusual properties including strong self-association and an affinity for lipid bilayers.

Growing community of inventors

Shaker Heights, OH, United States of America

James Thomas Anderson